This bill aims to impose stricter requirements on healthcare providers prescribing, dispensing, or administering mifepristone and other abortion drugs. It mandates that a REMS-certified provider must conduct an in-person visit with the patient before providing these medications. Furthermore, the provider must possess a medical license in the State where the patient resides to legally prescribe these drugs. Any provider who knowingly violates these provisions will face the loss of their REMS-certified status for a minimum period of two years, preventing them from prescribing these medications. The legislation broadly defines "abortion drug" to include any substance intended to intentionally terminate a pregnancy, with specific exclusions for live birth, removal of a dead unborn child, or treatment of an ectopic pregnancy. Additionally, the Secretary of Health and Human Services is required to submit annual reports to Congress detailing providers who have lost their REMS-certified status due to violations or improper prescribing practices.